Introduction of FDA guidance for dealing with drug shortage in public health emergency
Drug Evaluation Research
; 43(6):987-990, 2020.
Article
in Chinese
| CAB Abstracts | ID: covidwho-1352922
ABSTRACT
In light of the Coronavirus Disease 2019 (COVID-19) public health emergency in America, FDA issued Notifying FDA of a Permanent Discontinuance or Interruption in Manufacturing Under Section 506C of the FD&C Act Guidance for Industry in March 2020. This guidance aimed to assist applicants and manufacturers in providing FDA timely, informative notifications about changes in the production of certain drugs and biological products, in turn, help the Agency in its efforts to prevent or mitigate shortages of such products, so as to ensure the stability of the medical product supply chain in America. This guidance was still useful for perfecting interruption in manufacturing reporting system of China.
Full text:
Available
Collection:
Databases of international organizations
Database:
CAB Abstracts
Language:
Chinese
Journal:
Drug Evaluation Research
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS